文献速递炎症性肠病

特殊人群炎症性肠病的管理:肥胖、老年与妊娠患者

Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-11-08

本文综述了肥胖、老年和妊娠炎症性肠病(IBD)患者的管理挑战与对策。全球约1/3的IBD患者肥胖,肥胖与缓解困难、复发风险高、住院负担重及生物制剂反应差相关。老年IBD患者比例上升,需权衡疾病与治疗风险;妊娠期管理强调孕前及孕期疾病控制,多数高效疗法在孕期和哺乳期安全。

要点

  • 约1/3的IBD患者肥胖,肥胖与缓解困难、复发风险高及生物制剂反应差相关。
  • 老年IBD患者需权衡疾病相关与治疗相关并发症风险,并考虑合并症及功能状态。
  • 妊娠期IBD管理强调孕前及孕期主动控制疾病,多数高效疗法在孕期和哺乳期安全。

核心结论

  • 肥胖、老年和妊娠IBD患者的管理需针对其独特挑战采取个体化策略。
  • 肥胖与IBD缓解困难、复发风险高、住院负担重及生物制剂反应差相关。
  • 妊娠期IBD管理强调孕前及孕期优化疾病控制,多数高效疗法在孕期和哺乳期安全。

研究设计与样本

  • 综述,讨论肥胖、老年和妊娠IBD患者的管理挑战与解决方案。

主要发现

  • 全球肥胖流行背景下,约1/3的IBD患者肥胖,肥胖与缓解困难、复发风险高、住院负担和费用增加相关。
  • 肥胖患者对生物制剂治疗的反应较差,与药代动力学改变和肥胖介导的慢性炎症有关。
  • 预计未来十年内近1/3的IBD患者年龄超过60岁,老年患者诊断和治疗面临独特困境。
  • 妊娠期IBD管理需主动、多学科协作,强调孕前及孕期最佳疾病控制,继续高效疗法可降低不良母婴结局风险。

临床怎么用

  • 对肥胖IBD患者应考虑到缓解困难及生物制剂反应差的风险,并关注手术挑战。
  • 老年IBD患者管理需结合个体价值观、偏好、功能状态和合并症,权衡疾病与治疗风险。
  • 妊娠IBD患者应在孕前及孕期主动控制疾病,多数高效疗法在孕期和哺乳期可继续使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The epidemiology of inflammatory bowel disease (IBD) is progressively evolving impacting the type of patients with IBD we will see in clinical practice. In this review, we discuss specific challenges and solutions in the management of (1) obese, (2) older and (3) obstetric (pregnant) patients with IBD. With the global obesity epidemic, almost 1 in 3 patients with IBD are obese. Obesity is associated with greater difficulty in achieving remission, higher risk of disease relapse and higher burden and costs of hospitalization in patients with IBD. Obese patients also have inferior response to biologic therapy related to altered pharmacokinetics and obesity-mediated chronic inflammation. Surgical management of obese patients with IBD is also challenging. Similar to obesity, the prevalence of IBD in older patients is rising and it is anticipated that almost one-third of patients with IBD will be older than 60 years within the next decade. Older patients present unique diagnostic and therapeutic dilemmas, and management of these individuals warrants careful consideration of the risks of disease-related versus treatment-related complications, non-IBD-related extra-intestinal complications (eg, cardiovascular disease, malignancy), in the context of individual values, preferences, functional status and comorbidities. With evolving therapeutics, medical management of IBD surrounding pregnancy continues to be challenging. Overall, the management of pregnant patients requires a pro-active, multidisciplinary approach, with an emphasis on optimal disease control not just during, but prior to pregnancy. This often involves continuation of highly effective therapies, of which the vast majority are safe during pregnancy and breastfeeding, resulting in a reduction of risk of adverse maternal fetal outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Picardo S, Seow CH, et al. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin Gastroenterol Hepatol. 2019. PMID: 31712084. doi:10.1016/j.cgh.2019.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。